1. Prime Editing of Vascular Endothelial Growth Factor Receptor 2 Attenuates Angiogenesis In Vitro .
- Author
-
Ma G, Qi H, Deng H, Dong L, Zhang Q, Ma J, Yang Y, Yan X, Duan Y, and Lei H
- Subjects
- Humans, CRISPR-Associated Protein 9 metabolism, CRISPR-Associated Protein 9 genetics, CRISPR-Cas Systems, Genetic Vectors, Neovascularization, Pathologic metabolism, Phosphorylation, Retina metabolism, RNA, Guide, CRISPR-Cas Systems, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor A genetics, Angiogenesis metabolism, Endothelial Cells metabolism, Gene Editing methods, Vascular Endothelial Growth Factor Receptor-2 metabolism, Vascular Endothelial Growth Factor Receptor-2 genetics
- Abstract
Vascular endothelial growth factor receptor (VEGFR)-2 is a key switch for angiogenesis, which is observed in various human diseases. In this study, a novel system for advanced prime editing (PE), termed PE6h, is developed, consisting of dual lentiviral vectors: (1) a clustered regularly interspaced palindromic repeat-associated protein 9 (H840A) nickase fused with reverse transcriptase and an enhanced PE guide RNA and (2) a dominant negative (DN) MutL homolog 1 gene with nicking guide RNA. PE6h was used to edit VEGFR2 (c.18315T>A, 50.8%) to generate a premature stop codon (TAG from AAG), resulting in the production of DN-VEGFR2 (787 aa) in human retinal microvascular endothelial cells (HRECs). DN-VEGFR2 impeded VEGF-induced phosphorylation of VEGFR2, Akt, and extracellular signal-regulated kinase-1/2 and tube formation in PE6h-edited HRECs in vitro . Overall, our results highlight the potential of PE6h to inhibit angiogenesis in vivo .
- Published
- 2024
- Full Text
- View/download PDF